CJC-1295 and Ipamorelin: What the Evidence Actually Shows

CJC-1295 is a synthetic GHRH analog; Ipamorelin is a selective growth hormone secretagogue. Online culture sells the pair as a GH-axis "stack." Honest readout: published human data largely describe each ingredient separately (and for CJC-1295, mainly the with-DAC form); a strong peer-reviewed package proving everyday body-composition, recovery, or anti-aging claims for the combination is missing; and there is no FDA-approved CJC-1295 + Ipamorelin finished drug for those uses. Synergy talk is not combination trial proof — and neither peptide is somatropin.

CJC-1295 stimulates pituitary GH release via GHRH pathways. Literature often splits two related forms: With DAC (Drug Affinity Complex) — Albumin-binding linker; longer half-life; form in the main healthy-adult trials — Do not paste those results onto "no-DAC" products. Without DAC (Modified GRF 1-29 / Mod-GRF) — Shorter-acting analog without the DAC linker — Lacks the same published human package; do not invent equivalence.

Ipamorelin is a selective GH secretagogue with relatively little ACTH/cortisol signal versus older GHRPs in animal characterization. Human efficacy data are sparse; a Phase 2 postoperative-ileus study did not meet its primary endpoint — not a gym "recomp" win.

What the stack is not: an FDA-approved medicine; brand-equivalent to somatropin; proof that two GH-axis peptides equal approved GH therapy; or a DIY recipe. This page invents no dosing, units, or injection schedules.

Status — Typical CJC / Ipamorelin vial or "stack" prep: compounded prep, RUO labeling, or unapproved marketing — FDA-approved GH product (e.g., somatropin): NDA/BLA pathway; labeled indications. Quality — Variable identity (DAC vs no-DAC), purity, sterility — Lot controls; pharmacovigilance. Evidence — Ingredient studies ≠ stack RCTs for "optimization" — Substantial evidence for labeled uses. Sameness — Not somatropin or other approved GH products — Recombinant GH with labeled indications. Scoreboard — We do not source or recommend research-only products sold for human use — Clinician-supervised, legitimate pathways only.

FDA has flagged peptide impurity/immunogenicity concerns and listed safety-risk language for CJC-1295 (heart-rate and vasodilatory reaction reports; limited clinical data) and Ipamorelin acetate (immunogenicity concerns; serious AEs including death noted in an IV gastric-motility study context — causality not fully settled). Nomination history and advisory votes do not equal FDA drug approval. RUO peptides sold with lifestyle claims are the highest-risk channel for purity, sterility, and dose chaos.

Molecules — GHRH analog + selective secretagogue — "Natural GH therapy in a vial". CJC-1295 with DAC — Healthy-adult trials (Teichman et al., JCEM 2006) showed multi-day GH/IGF-I rises — Those results apply to every online "CJC" label. CJC-1295 without DAC — Shorter-acting GHRH-analog relative — Same published package as with-DAC. Ipamorelin alone — Selective GH-release characterization (Raun 1998); limited clinical efficacy — Proven fat-loss / muscle / sleep drug. The stack — Dual-receptor rationale is a hypothesis; stack evidence ≠ single-ingredient evidence — Combination RCTs prove "recomp" or anti-aging vs somatropin. Different modality and labels — "Same as HGH / Genotropin / Norditropin". Sport — GH-releasing factors / secretagogues generally prohibited — "Research peptide, so athletes are fine".

If a strong published human RCT for the claimed stack use does not exist: unproven for that use in humans.

Scientific interest is real — Clear pituitary pharmacology. Interest ≠ approved "optimization" therapy. Men ask for a reason — Recovery, body composition, and sleep dominate search. Curiosity ≠ certainty. Ingredient data ≠ stack proof — Signals for one CJC form or Ipamorelin alone do not finish a blend package. Evaluation beats a vial — Sleep, training, nutrition, and indicated labs often explain the symptom better than a peptide nickname. Skipping RUO products means fewer sterility unknowns and fewer anti-doping landmines.

Unapproved status — No FDA-approved finished stack for optimization uses — Not an approved therapeutic. Compounding / RUO — 503A/503B pathways ≠ influencer charts; gray-market RUO risks purity/sterility chaos — Advisory votes ≠ drug approval. Immunogenicity & impurities — Peptide impurity/immune concerns for some routes — FDA bulk-substance safety-risk language. Cardiac / systemic — CJC-1295: heart-rate and vasodilatory reaction reports; limited data — Missing long-term safety database is a risk. Ipamorelin clinical gaps — Serious AEs (including death) flagged in FDA discussion of an IV motility study — Caution, not a green light. Metabolic / IGF-I — GH-axis stimulation is not risk-free — Do not assume "secretagogue = safer than GH". Anti-doping / false equivalence — Generally prohibited for tested athletes; not somatropin — WADA/USADA; delayed real evaluation.

We do not source or recommend research-only products sold for human use. This is not a DIY dosing guide — no microgram schedules, reconstitution recipes, or injection instructions appear here.

May discuss with a licensed clinician: men who want an evidence-first talk on GH-axis peptide claims; patients already in clinician-guided pathways who need a reality check on "stack" marketing; athletes who must confirm WADA/USADA status; anyone considering peptides without labs, meds review, and goal clarification.

Should avoid self-directed experiments: competitive/tested athletes; men with active malignancy concerns or unfinished oncology workups; people with uncontrolled diabetes, significant cardiovascular disease, or untreated pituitary disease without oversight; anyone shopping "research only" vials; anyone expecting guaranteed muscle, fat-loss, or anti-aging timelines.

Scoreboard Health is education-first and clinician-guided. Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only. Soft links below support general evaluation pathways only — not a way to obtain this stack.

There is no FDA-approved CJC-1295 + Ipamorelin finished drug for the uses marketed online. Do not treat it as brand-equivalent to somatropin or other approved GH products. Approach — What it generally is — Education pointer: FDA-approved somatropin (e.g., Genotropin, Norditropin, Omnitrope) — Recombinant GH with labeled indications — Different class and package — not this stack. FDA-approved GHRH analog (tesamorelin / Egrifta) — Labeled for specific HIV lipodystrophy use — Not a gym "CJC substitute". Compounded CJC and/or Ipamorelin (if under finished FDA compounding rules) — Pharmacy-prepared — not an approved finished drug — Compounding ≠ approval; DAC vs no-DAC matters. RUO / research-chem vials — Lab-labeled materials diverted to humans — We do not source or recommend research-only products sold for human use. Peptide "stacks" — Multi-ingredient protocols sold as synergy (e.g., with BPC-157) — Ingredient evidence ≠ combination evidence.

1. Is the CJC-1295 + Ipamorelin stack FDA-approved? No. No FDA-approved finished drug of this combination exists for muscle, recovery, fat-loss, or anti-aging uses as of September 2026.

2. Does a single-ingredient study prove the stack works? No. Stack evidence ≠ single-ingredient evidence. Synergy talk is not a substitute for combination trials.

3. Is CJC-1295 with DAC the same as without DAC? No. With-DAC literature (including the main healthy-adult JCEM work) should not be pasted onto no-DAC / Modified GRF products.

4. Is this the same as HGH / somatropin? No. Do not claim sameness to Genotropin, Norditropin, Omnitrope, or other labeled somatropin products.

5. What about research-use-only CJC or Ipamorelin online? RUO labeling does not make human injection safe or appropriate. We do not source or recommend research-only products sold for human use.

6. Can I dose it from a forum chart? No DIY dosing, units, reconstitution, or injection schedules appear here. Ask a licensed clinician.

7. Is "compounded" the same as "FDA-approved"? No. An approved drug has completed FDA's drug-approval process for a labeled use; compounding is a separate pathway.

8. Are these peptides banned in sport? GH-releasing factors and related secretagogues are generally prohibited for WADA-tested athletes. Confirm current WADA/USADA status.

9. What did Ipamorelin's human efficacy trial show? A Phase 2 postoperative-ileus study did not meet its primary endpoint — not proof of gym or anti-aging benefit.

10. How does Scoreboard approach stack questions? Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only. Education first and a hard line against research-only products sold for human use. Soft links to How it works / Treatments are general evaluation pathways — not a stack request. See /how-it-works and /treatments.

Bottom line: CJC-1295 and Ipamorelin are often paired as a GH-axis stack, but they are not FDA-approved finished drugs for optimization uses. Distinguish with-DAC vs without-DAC when reading papers; do not equate ingredient signals with combination proof; and do not treat the stack as somatropin.

So what? Get a real evaluation — history, labs when indicated, sleep/training/nutrition context, meds review, and anti-doping reality if you compete.

We do not source or recommend research-only products sold for human use. Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only. Soft next steps are for general men's health evaluation pathways — not a way to "get" CJC-1295, Ipamorelin, or this stack. To learn how Scoreboard structures clinician-guided evaluation and monitoring, see: How it works · Treatments (current catalog offerings — this stack is not offered).